Navigation Links
Trius Doses First Patient in Antibacterial Phase 2 Trial
Date:9/21/2008

TR-701 Tested for Efficacy in Drug Resistant Skin Infections

SAN DIEGO, Sept. 22 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the initiation of Phase 2 testing of the oral form of its second-generation oxazolidinone antibacterial drug TR-701. The multicenter trial will test the efficacy, safety and tolerability of once-daily doses of 200, 300 and 400 milligrams of TR-701 in complicated skin and skin structure infections (cSSSI) for five to seven days of treatment.

The study follows the recently completed two-part Phase 1 study that tested the safety, tolerability and pharmacokinetics of TR-701 in single and multiple ascending doses for up to 21 days compared with Zyvox(R) (linezolid), the only marketed drug of the oxazolidinone class. In addition, separate food effect and microdialysis studies measuring the absorption of TR-701 in the presence and absence of food and the tissue penetration of the drug, respectively, have also been completed.

Results of the Phase 1 trials will be presented at the joint annual meetings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Diseases Society of America (IDSA) in Washington, D.C in October 2008.

"Our Phase 1 study results indicate that TR-701 will be a once-daily drug with the potential to offer patients several important advantages over linezolid as well as other marketed drugs," said Philippe Prokocimer, M.D., Chief Medical Officer of Trius. "The intent of Phase 2 will be to validate these observations in a patient population and to select a therapeutic dosing regimen from the three doses being tested."

"The growing epidemic of MRSA in the hospital and community leaves few viable treatment options for patients requiring an oral drug," said Jeffrey Stein, Ph.D., Chief Executive Officer of Trius. "We believe that the once-daily dosing and short course of TR-701 therapy of five to seven days will offer a clinical advantage fo
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PacificGMP Completes GMP Product Fill for Trius Therapeutics
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
5. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
7. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
8. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
9. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
10. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
11. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- Gateway Analytical announced today that they ... Annual Global Pharma Manufacturing Summit in ... The Global Pharma Manufacturing Summit offers a networking ... biologic pharmaceutical manufacturing. The conference is focused on ... such as the increasing pressure to grow and ...
(Date:8/28/2014)... Telik, Inc. (OTCQB: TELK), a clinical ... MabVax Therapeutics, Inc. on July 8, 2014, announced ... the development of its lead antibody program designated ... Company,s internally developed antibody discovery platform.  These preclinical ... based therapeutic and diagnostic products based on this ...
(Date:8/28/2014)... 2014  Rx Safes, Inc., the manufacturer of fingerprint ... waging a new war on drugs to reduce prescription ... More than 2,500 children a day experiment with ... are easily accessed from unsecured medicine cabinets, closets and drawers. ... streets, Rx Safes will address the new age drug ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Rx Safes, Inc. Announces New War On Drugs 2
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
(Date:8/28/2014)... identify themselves as ,old, feel worse about their own ... value than younger age groups. , New research from ... and ill, across different countries: social status, age identification ... European Social Survey. Respondents, who were all aged 70 ... researchers found that those living in societies where older ...
(Date:8/28/2014)... New York (PRWEB) August 28, 2014 ... currently perceived with great interest among other healthcare industry ... to the high demand in vaccine with respect to ... highly in demand due to an improved understanding for ... across the United States. It has led to new ...
(Date:8/28/2014)... August 28, 2014 After more than ... Vitenas is excited to announce the opening of ... kind in any city, Mirror Mirror Beauty Boutique offers ... Situated on the corner of Richmond and Drexel near ... luxurious amenities, and cutting-edge technology in a private, easy ...
(Date:8/28/2014)... By Steven Reinberg ... -- Treating pre-cancerous skin spots with a type of light ... freezing the lesions with liquid nitrogen, a new study suggests. ... on the scalp and face of people with fair complexions ... review of prior research found that people who underwent the ...
(Date:8/28/2014)... Lansdale, pA (PRWEB) August 28, 2014 ... is now available throughout the world, with large ... such services. Since laboratories differ with regard to ... times, and costs, payers may struggle to find ... testing needs. To help clients sort through these ...
Breaking Medicine News(10 mins):Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2
... On the third anniversary,of Hurricane Katrina, with ... America,s Health (TFAH) issued the following statement, along,with ... to major,emergencies. TFAH also provides a set of ... the next potential health emergency based on,TFAH,s annual ...
... SEATTLE, Aug. 29 Attorneys representing consumers in ... illegally rigging the price of,virtually every prescription drug ... preparing for a trial set for December 1 ... http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ), Attorney Steve W. Berman filed ...
... that Obama failed to address the issue, ... Convention Wednesday night, Former President Bill Clinton called,for ... in the,United States. In praising Presidential nominee Barack ... nation,s commendable global leadership in,an area in which ...
... normal development, mouse study finds , , FRIDAY, Aug. 29 (HealthDay ... short period in early pregnancy may cause fetal problems, suggest ... initial signs of fetal alcohol syndrome, which affects one in ... high upper lip, small eye openings, and a short nose. ...
... BRISBANE, Calif., Aug. 29 InterMune, Inc.,(Nasdaq: ITMN ... and,President of InterMune, will present at the Thomas Weisel ... 10:55 a.m. EDT., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
... MYA Cosmetic Surgery Seems to be the Provider of Choice ... Will be Next?, Months of constant cameras, mirrors all ... can have a major impact on how you feel,about the ... has,become a reality. Upon leaving the house contestants may undoubtedly ...
Cached Medicine News:Health News:On the Third Anniversary of Hurricane Katrina; Trust for America's Health Questions State of National Emergency Preparedness 2Health News:On the Third Anniversary of Hurricane Katrina; Trust for America's Health Questions State of National Emergency Preparedness 3Health News:On the Third Anniversary of Hurricane Katrina; Trust for America's Health Questions State of National Emergency Preparedness 4Health News:Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation 2Health News:Hagens Berman Sobol Shapiro: Attorneys Representing Consumers Prepare for $12 Billion RICO Trial Against McKesson for Alleged Drug Price Manipulation 3Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 2Health News:Bill Clinton and Other Leaders Call For 'Renewal of Battle Against AIDS' in the United States at Democratic Convention 3Health News:Alcohol in Early Pregnancy May Prompt Fetal Cell Death 2Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3
BETADINE Solution Swab Aid antiseptic pads are for quick and easy skin degerming. Individually wrapped pads, saturated with 10% povidone-iodine solution, offer the advantages of BETADINE Solution in ...
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection....
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness....
Medicine Products: